ENSG vs INDV
Ensign Group vs Indivior Pharmaceuticals Inc — AI-powered side-by-side comparison
VS
INDV
Indivior Pharmaceuticals Inc
58
Watch
| Metric | ENSG | INDV |
|---|
| AI Score |
69
|
58
|
| Price |
$180.10
|
$38.42
|
| P/E Ratio |
27.43×
|
13.53×
|
| ROE |
15.4%
|
-214.3%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
14.1%
|
83.9%
|
| Debt / Equity |
0.92×
|
-2.45×
|
| Dividend Yield |
0.1%
|
0.0%
|
| RSI (14) |
71.8
|
42.6
|
| Beta |
0.694
|
1.0251
|
| Expected Upside |
+5.3%
|
—
|
AI Committee View
Current Innellis committee reasoning for ENSG versus INDV.
ENSG leads by 11 points.
ENSG scores 69/100 (Buy) versus INDV at 58/100 (Watch).
ENSG Committee View
50% agreement
4 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- RSI at 72 is in overbought territory — Technical
INDV Committee View
50% agreement
6 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — high leverage (debt-to-equity 5.43) amplifies downside in a stress scenario. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- P/E of 12.8 is inexpensive for the broad market — Value
- ROE of 159.1% shows genuine earnings power backing the valuation — Value
- EPS growing 237.5% YoY — Growth
Bear Case
- Price-to-book of 49.6x prices in significant intangible value — Value
- Debt-to-equity of 5.43 adds balance-sheet risk to the value case — Value
- MACD histogram negative -- bearish momentum — Technical